The latest news on the upcoming launch of Anagrelide in the country

Anagrelide (Anagrelide), as an internationally recognized essential thrombocythemia (ET) treatment drug, has attracted increasing attention in the Chinese market in recent years. At present, the original drug of anagrelide has not yet been officially marketed in mainland China, but domestic companies have successfully developed generic versions. According to the latest announcement from the drug regulatory department, domestically produced anagrelide tablets have been approved for the treatment of essential thrombocythemia, which means that Chinese ET patients will soon have new treatment options.

Currently, domestically produced anagrelide on the domestic market has not been included in the scope of medical insurance reimbursement, and the price per box is about 7,000 yuan. Due to different pricing and distribution channels, the specific price may fluctuate slightly depending on the region and hospital. Patients can consult the local hospital pharmacy or regular drug channels for the latest price information. Compared with original drugs that have been on the overseas market for many years (such as the U.S. Shire preparation), domestic anagrelide still has room for price decline, but its efficacy and bioequivalence have reached international standards.

Judging from clinical feedback, the pharmacological effects of domestic anagrelide are basically the same as those of the original drug, and it performs well in controlling platelet levels and reducing the risk of thrombosis. Some hospitals have included it in the rare disease treatment drug catalog to support the standardized treatment of ET patients. In the future, as more companies participate in production and medical insurance negotiations advance, its price is expected to drop further, thereby reducing patients' long-term medication burden.

It is worth noting that anagrelide is a prescription drug and should be prescribed by a hematologist or oncologist based on blood results and a comprehensive assessment of the condition. Platelet levels and cardiovascular responses need to be closely monitored in the early stages of treatment to avoid the risk of bleeding due to over-suppression.

Overall, the gradual introduction of anagrelide in the Chinese market not only means the diversification of ET treatment methods, but also represents a major progress in the management of rare blood diseases in my country.

Reference materials:https://go.drugbank.com/drugs/DB00261